Recent events
Recent events tied to this brand in public sources.
Back to profile48 entries · Page 1 of 3
2026
Nxera and AbbVie enter global licensing agreement for NXE0033744
Nxera Pharma entered into an exclusive global licensing agreement with AbbVie for NXE0033744, an investigational oral EP4 receptor agonist being developed for inflammatory bowel disease. AbbVie will receive exclusive worldwide rights to develop and commercialise the candidate for IBD; the transaction remains subject to customary antitrust clearances.
2026
AbbVie completes acquisition of Apogee Therapeutics
AbbVie completed its acquisition of Apogee Therapeutics, as reported in the release dated Oct. 30.
2026
US FDA approves AbbVie's drug for Parkinson's disease
The US Food and Drug Administration approved AbbVie's drug for Parkinson's disease, as reported by Reuters.
2026
AbbVie reports third-quarter 2026 results
AbbVie reported third-quarter 2026 revenue of $17.404 billion, up 10.3% year over year, and adjusted EPS of $3.82.
2026
AbbVie raises full-year adjusted EPS guidance
AbbVie raised its full-year adjusted EPS guidance from $13.76–$13.96 to $13.95–$13.99.
2024
AbbVie completes acquisition of ImmunoGen
AbbVie announced that it had completed its previously announced acquisition of ImmunoGen.
2024
AbbVie cuts first-quarter earnings outlook
AbbVie revised down its first-quarter adjusted income-per-share outlook to $2.26–$2.30 from its previous $2.30–$2.34 range. It reaffirmed its annual adjusted income-per-share outlook of $11.05–$11.25.
2024
DISCO Pharmaceuticals raises €20 million in seed financing
DISCO Pharmaceuticals raised €20 million in seed financing, backed by an investor syndicate that included Sofinnova Partners, Panakes Partners, M Ventures and AbbVie Ventures.
2023
AbbVie announces acquisition of Cerevel Therapeutics
AbbVie announced it will acquire Cerevel Therapeutics for $45 per share in cash, valuing the drugmaker at about $8.7 billion. The transaction is subject to regulatory approvals, Cerevel shareholder approval and other customary closing conditions.
2023
AbbVie announces acquisition of Mitokinin
AbbVie announced its acquisition of discovery-stage biotechnology company Mitokinin in a deal worth over $650 million. The agreement gives AbbVie access to Mitokinin’s lead PINK1 activator compound; Mitokinin’s shareholders are eligible for additional payments tied to development and commercial milestones, as well as royalties.
2023
AbbVie completes acquisition of Mitokinin
AbbVie exercised its exclusive right and completed its acquisition of biotechnology company Mitokinin. Under the agreement, AbbVie will pay Mitokinin shareholders $110 million at closing, with potential additional milestone payments and royalties.
2023
FDA approves EPKINLY for adults with DLBCL
The U.S. Food and Drug Administration approved EPKINLY to treat adults with relapsed or refractory diffuse large B-cell lymphoma.
2023
AbbVie files patent lawsuit against BeiGene over Brukinsa
AbbVie’s Pharmacyclics unit filed a lawsuit against BeiGene in federal court in Delaware, alleging that BeiGene’s Brukinsa infringes a patent on AbbVie’s Imbruvica. AbbVie sought a declaratory judgment of infringement and damages; BeiGene said it would vigorously defend against the allegations.
2023
FDA approves Linzess for pediatric functional constipation
The FDA approved Linzess as a treatment for functional constipation in patients aged 6 to 17 years, making it the first therapy approved for pediatric functional constipation, according to the agency release.
2023
FDA grants accelerated approval to Epkinly
The FDA granted accelerated approval to epcoritamab-bysp (Epkinly), marketed by Genmab and AbbVie, for adults with relapsed or refractory diffuse large B-cell lymphoma. Full approval for the indication depends on further confirmation of clinical benefit in confirmatory trials.
2022
AbbVie terminates collaboration with BioArctic
BioArctic announced that AbbVie decided to terminate their collaboration concerning the alpha-synuclein antibody portfolio, including ABBV-0805.
2022
AbbVie announces acquisition of Syndesi Therapeutics
AbbVie announced its acquisition of Syndesi Therapeutics under a $1 billion agreement, including a $130 million upfront payment and milestone payments of up to $870 million.
2022
AbbVie acquires Syndesi Therapeutics
Novo Holdings announced that its portfolio company Syndesi Therapeutics had been acquired by AbbVie in a deal valued at up to US$1 billion, including US$130 million upfront.
2022
FDA approves Skyrizi for active psoriatic arthritis in adults
The FDA approved AbbVie’s risankizumab-rzaa (Skyrizi) for treating adults with active psoriatic arthritis, expanding its indication beyond plaque psoriasis. The article does not state the approval date.
2021
FDA approves RINVOQ for psoriatic arthritis
The U.S. Food and Drug Administration approved AbbVie’s RINVOQ for adults with active psoriatic arthritis who had an inadequate response or intolerance to one or more tumor necrosis factor blockers.